WO2003093313A3 - Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein - Google Patents

Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein Download PDF

Info

Publication number
WO2003093313A3
WO2003093313A3 PCT/EP2003/004425 EP0304425W WO03093313A3 WO 2003093313 A3 WO2003093313 A3 WO 2003093313A3 EP 0304425 W EP0304425 W EP 0304425W WO 03093313 A3 WO03093313 A3 WO 03093313A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor viii
interaction
antagonists
low
lrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/004425
Other languages
French (fr)
Other versions
WO2003093313A2 (en
Inventor
Koenraad Mertens
Arend Niels Bovenschen
Jan Voorberg
Manfred Rieger
Friedrich Scheiflinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Stichting Sanquin Bloedvoorziening
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Stichting Sanquin Bloedvoorziening
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Stichting Sanquin Bloedvoorziening, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to AU2003227687A priority Critical patent/AU2003227687B2/en
Priority to DK03725109.7T priority patent/DK1497330T3/en
Priority to DE60332011T priority patent/DE60332011D1/en
Priority to EP03725109A priority patent/EP1497330B1/en
Priority to JP2004501452A priority patent/JP2005535588A/en
Priority to AT03725109T priority patent/ATE463514T1/en
Priority to US10/512,907 priority patent/US8586538B2/en
Priority to CA2484155A priority patent/CA2484155C/en
Publication of WO2003093313A2 publication Critical patent/WO2003093313A2/en
Publication of WO2003093313A3 publication Critical patent/WO2003093313A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A. The present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor Vlll half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A.
PCT/EP2003/004425 2002-04-29 2003-04-28 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein Ceased WO2003093313A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2003227687A AU2003227687B2 (en) 2002-04-29 2003-04-28 Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein
DK03725109.7T DK1497330T3 (en) 2002-04-29 2003-04-28 Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein
DE60332011T DE60332011D1 (en) 2002-04-29 2003-04-28 ANTAGONISTS OF INTERACTION BETWEEN FACTOR VIII AND LRP (LOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN)
EP03725109A EP1497330B1 (en) 2002-04-29 2003-04-28 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
JP2004501452A JP2005535588A (en) 2002-04-29 2003-04-28 Antagonists of the interaction between factor VIII and low density lipoprotein receptor-related proteins
AT03725109T ATE463514T1 (en) 2002-04-29 2003-04-28 ANTAGONISTS OF THE INTERACTION BETWEEN FACTOR VIII AND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß)
US10/512,907 US8586538B2 (en) 2002-04-29 2003-04-28 Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII
CA2484155A CA2484155C (en) 2002-04-29 2003-04-28 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37635102P 2002-04-29 2002-04-29
US60/376,351 2002-04-29

Publications (2)

Publication Number Publication Date
WO2003093313A2 WO2003093313A2 (en) 2003-11-13
WO2003093313A3 true WO2003093313A3 (en) 2004-07-29

Family

ID=29401334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004425 Ceased WO2003093313A2 (en) 2002-04-29 2003-04-28 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein

Country Status (10)

Country Link
US (1) US8586538B2 (en)
EP (1) EP1497330B1 (en)
JP (2) JP2005535588A (en)
AT (1) ATE463514T1 (en)
AU (1) AU2003227687B2 (en)
CA (1) CA2484155C (en)
DE (1) DE60332011D1 (en)
DK (1) DK1497330T3 (en)
ES (1) ES2343681T3 (en)
WO (1) WO2003093313A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592430B2 (en) 2003-09-10 2009-09-22 Amgen Fremont Antibodies to M-CSF

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP1454632A1 (en) * 2003-02-07 2004-09-08 Aventis Behring GmbH, Intellectual Property/Legal Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides
WO2006003183A1 (en) * 2004-07-02 2006-01-12 Alois Jungbauer Peptides for blocking fviii inhibitors
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009274958A (en) 2006-08-31 2009-11-26 Nara Prefecture Antibody promoting activation of blood coagulation factor viii
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CA2726942A1 (en) * 2008-06-04 2009-12-10 Bayer Healthcare Llc Fviii muteins for treatment of von willebrand disease
KR101648734B1 (en) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
JP5394864B2 (en) * 2009-09-10 2014-01-22 アスモ株式会社 motor
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
EP2616486B1 (en) 2010-09-15 2019-01-02 Stichting Sanquin Bloedvoorziening Factor viii variants having a decreased cellular uptake
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CA2953593C (en) 2014-07-02 2023-09-26 Csl Limited Modified von willebrand factor
ES2772933T3 (en) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Modified von Willebrand factor that has an improved half-life
WO2016188905A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
RU2017145014A (en) 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг DIFFERENT POLYPEPTIDES OF THE VILLEBRAND VON FACTOR FOR THE TREATMENT OF HEMOPHILIA
WO2017117630A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated von willebrand factor
JP6851381B6 (en) 2016-01-07 2021-04-21 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Mutant cleavage type von Will brand factor
SG10201912360SA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
CA3043397A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041816A1 (en) * 1995-06-12 1996-12-27 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1095143E (en) * 1998-05-08 2008-11-28 Sanquin Bloedvoorziening Inhibitor for diagnosis and treatment of haemophilia a patients
EP1129186B2 (en) * 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening A factor viii-polypeptide with factor viii:c-activity
AT409335B (en) * 1998-11-10 2002-07-25 Immuno Ag PHARMACEUTICAL PREPARATION CONTAINING A RECEPTOR ANTAGONIST FOR THE TREATMENT OF BLOOD COagulation disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041816A1 (en) * 1995-06-12 1996-12-27 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOVENSCHEN N ET AL.: "Low Density Lipoprotein Receptor-related Protein and Factor IXa Share Structural Requirements for Binding to the A3 Domain of Coagulation Factor VIII", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 11, 14 March 2003 (2003-03-14), pages 9370 - 9377, XP002264413 *
LENTING P J ET AL: "THE SEQUENCE GLU-1811-LYS-1818 OF HUMAN BLOOD COAGULATION FACTOR VIII COMPRISES A BINDING SITE FOR ACTIVATED FACTOR IX", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 4, 26 January 1996 (1996-01-26), pages 1935 - 1940, XP002017258, ISSN: 0021-9258 *
NEELS JG ET AL.: "Interaction Between Factor VIII and LDL Receptor-related Protein", TRENDS IN CARDIOVASCULAR MEDICINE, vol. 10, 2000, pages 8 - 14, XP002264412 *
SAENKO EL ET AL.: "Role of the Low Density Lipoprotein-related Protein Receptor in Mediation of Factor VIII Catabolism", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 53, 31 December 1999 (1999-12-31), pages 37685 - 37692, XP002264411 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592430B2 (en) 2003-09-10 2009-09-22 Amgen Fremont Antibodies to M-CSF

Also Published As

Publication number Publication date
DK1497330T3 (en) 2010-06-14
ES2343681T3 (en) 2010-08-06
AU2003227687B2 (en) 2009-10-15
DE60332011D1 (en) 2010-05-20
AU2003227687A1 (en) 2003-11-17
EP1497330B1 (en) 2010-04-07
CA2484155C (en) 2015-10-13
JP2010202664A (en) 2010-09-16
ATE463514T1 (en) 2010-04-15
WO2003093313A2 (en) 2003-11-13
US8586538B2 (en) 2013-11-19
EP1497330A2 (en) 2005-01-19
JP2005535588A (en) 2005-11-24
CA2484155A1 (en) 2003-11-13
US20080219983A1 (en) 2008-09-11

Similar Documents

Publication Publication Date Title
WO2003093313A3 (en) Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
CY1110894T1 (en) METHODS FOR THE TREATMENT OR PREVENTION OF VASCULAR INFLAMMATION USING STEROLIS ABSORBTOR (S)
IS8432A (en) Antibodies that bind to leukocyte receptor-4
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
DE60116256D1 (en) COMPOSITIONS FOR THE DELIVERY OF CORTISOLANTAGONISTS
EA200500782A1 (en) TREATMENT OF HEMORRHAGIC SHOCK
WO2004091497A3 (en) Methods and compositions for increasing the anaerobic working capacity in tissues
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
JP2005535588A5 (en)
ATE500328T1 (en) VASCULAR ADHESION MOLECULES AND MODULATION OF THEIR FUNCTION
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2006135493A3 (en) A composition for wound healing and use thereof
DE602004005455D1 (en) METHOD FOR TREATING OR PREVENTING CHRONIC WOUNDS AND COMPLETE FOOD COMPOSITION WITH GLYCIN AND / OR LEUCINE FOR USE THEREIN
ATE386050T1 (en) PEPTIDES THAT BIND THE HEPARIN BINDING DOMAIN OF VEGF AND VEGFR-2
EP1240900A4 (en) Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
DE50214008D1 (en) MEDICAMENT FOR THE TREATMENT OF TUMORS AND THEIR METASTASES USING A BINDING MOLECULE AGAINST THE BONE SIALOPROTEIN
ATE265225T1 (en) PHARMACEUTICAL PREPARATION CONTAINING A RECEPTOR ANTAGONIST FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS
WO2006029487A3 (en) Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
WO2003003988A3 (en) Peptides which modulate blood coagulation and methods of use thereof
DE602004016547D1 (en) 1,4-DIHYDROPYRIDINE COMPOUNDS, PHARMACEUTICAL COMPOUNDS, AND METHOD FOR THE TREATMENT OF CARDIAC DISORDER
GB0211230D0 (en) Treatment of heart failure
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala
Hoffman et al. An activated factor VII variant with enhanced tissue factor‐independent activity speeds wound healing in a mouse hemophilia B model

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003725109

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2484155

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003227687

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004501452

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003725109

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10512907

Country of ref document: US